Advanced Therapies Week 2022 | CoupledCAR Platform Technology in solid tumors

Christopher Ballas, PhD, Innovative Cellular Therapeutics, Rockville, MD, discusses the mechanism of action of the CoupledCAR platform, which aims to overcome issues associated with targeting solid tumors with cell therapy. Dr Ballas describes the development of an anti-CD19 chimeric antigen receptor (CAR) T-cell with a PD-1 dominant negative receptor, which was found to induce proliferation of other T cells. This property enabled proliferation of CAR T-cells in solid tumors, which addresses issues relating to infiltration of cell therapies in solid tumors. This interview took place at Advanced Therapies Week 2022.